Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T13:30:42.742Z.
Calculation as of: 2026-10-06T13:30:42.742Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 8e18e4937bb179ad65bb801f5f057f36d78bd2e4af2c39ec5cecdad017acf428
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$36.26M
EV/EBIT Ratio
N/A
TTM Avg
50.30x
3Y Avg
467.13x
5Y Avg
265.91x
Market Cap
$38.34M
EV/EBIT Ratio
74.04x
TTM Avg
60.42x
3Y Avg
123.40x
5Y Avg
130.57x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| BriaCell Therapeutics Corp. (BCTX) | $36.54M | N/A | N/A | N/A | N/A |
| Elutia Inc (ELUT)vs › | $35.68M | N/A | N/A | N/A | N/A |
| HeartBeam, Inc. (BEAT)vs › | $34.65M | N/A | N/A | N/A | N/A |
| Elicio Therapeutics, Inc. (ELTX)vs › | $36.23M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $36.79M | N/A | 8.66x | 44.05x | 43.98x |
| Accuray Incorporated (ARAY)vs › | $36.26M | N/A | 50.30x | 467.13x | 265.91x |
| Edesa Biotech, Inc. (EDSA)vs › | $37.67M | N/A | N/A | N/A | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.34M | 74.04x | 60.42x | 123.40x | 130.57x |
| Incannex Healthcare Limited (IXHL)vs › | $38.41M | N/A | N/A | N/A | N/A |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.52M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
